281 related articles for article (PubMed ID: 27829292)
21. 5-Azacytidine for the treatment of myelodysplastic syndromes.
Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
[TBL] [Abstract][Full Text] [Related]
22. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
23. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Feld J; Tremblay D; Navada SC; Silverman LR
Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
25. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
Ozbalak M; Cetiner M; Bekoz H; Atesoglu EB; Ar C; Salihoglu A; Tuzuner N; Ferhanoglu B
Hematol Oncol; 2012 Jun; 30(2):76-81. PubMed ID: 21387357
[TBL] [Abstract][Full Text] [Related]
26. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
27. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
Ettou S; Audureau E; Humbrecht C; Benet B; Jammes H; Clozel T; Bardet V; Lacombe C; Dreyfus F; Mayeux P; Solary E; Fontenay M
Leukemia; 2012 Oct; 26(10):2297-9. PubMed ID: 22743624
[No Abstract] [Full Text] [Related]
28. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
29. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ
J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844
[TBL] [Abstract][Full Text] [Related]
30. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.
Voso MT; Lo-Coco F; Fianchi L
Curr Opin Oncol; 2015 Nov; 27(6):532-9. PubMed ID: 26352541
[TBL] [Abstract][Full Text] [Related]
32. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
33. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
[TBL] [Abstract][Full Text] [Related]
34. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
[TBL] [Abstract][Full Text] [Related]
35. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML.
Chatzilygeroudi T; Chondrou V; Boers R; Siamoglou S; Athanasopoulou K; Verigou E; Gribnau J; Alexis S; Labropoulou V; Kourakli A; Patrinos GP; Sgourou A; Symeonidis A
Clin Epigenetics; 2024 Jun; 16(1):79. PubMed ID: 38879530
[TBL] [Abstract][Full Text] [Related]
36. 5-Azacytidine/Azacitidine.
Müller A; Florek M
Recent Results Cancer Res; 2010; 184():159-70. PubMed ID: 20072837
[TBL] [Abstract][Full Text] [Related]
37. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Bally C; Thépot S; Quesnel B; Vey N; Dreyfus F; Fadlallah J; Turlure P; de Botton S; Dartigeas C; de Renzis B; Itzykson R; Fenaux P; Adès L
Leuk Res; 2013 Jun; 37(6):637-40. PubMed ID: 23499498
[TBL] [Abstract][Full Text] [Related]
38. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
39. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
Santini V
Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
[TBL] [Abstract][Full Text] [Related]
40. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Daher-Reyes GS; Merchan BM; Yee KWL
Expert Opin Investig Drugs; 2019 Oct; 28(10):835-849. PubMed ID: 31510809
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]